Lv21
120 积分 2023-04-09 加入
Revisiting fibrosis in inflammatory bowel disease: the gut thickens
2天前
已完结
Navigating the complexities of drug development for inflammatory bowel disease
20天前
已完结
Efficacy of Ustekinumab Optimization by 2 Initial Intravenous Doses in Adult Patients With Severe Crohn’s Disease
4个月前
已完结
Bevacizumab and gastrointestinal perforations: a review from the FDA Adverse Event Reporting System (FAERS) database
5个月前
已完结
Ocrelizumab-related neutropenia: Effects of age, sex and bodyweight using the FDA Adverse Event Reporting System (FAERS)
5个月前
已完结
Tofacitinib in Acute Severe Ulcerative Colitis (TACOS): A Randomized Controlled Trial
5个月前
已完结
Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study
5个月前
已完结
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease
6个月前
已完结
Endoscopic scores for inflammatory bowel disease in the era of ‘mucosal healing’: Old problem, new perspectives
8个月前
已完结
The Natural History of Adult Crohn's Disease in Population-Based Cohorts
9个月前
已完结
皖公网安备34019202002308
